Atopic Dermatitis Clinical, Companies, Therapy Assessment, Therapies, Pipeline | Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVer

DelveInsight's, "Atopic Dermatitis - Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis indicates that the Atopic Dermatitis pipeline features over 100 active companies dedicated to advancing more than 120 therapeutic candidates for the treatment of Atopic Dermatitis.

Atopic Dermatitis Overview:

Atopic Dermatitis (AD), widely referred to as eczema, is a chronic inflammatory skin condition that typically appears in early childhood but can emerge at any stage of life, often persisting or recurring over time. The word dermatitis originates from "derm" (skin) and "itis" (inflammation), emphasizing the condition's inflammatory nature. AD is characterized by itching, redness, and rashes, which result from a complex interplay of genetic susceptibility, immune system hyperactivity, environmental triggers, allergens, and infections.

Almost 50% of people with moderate-to-severe eczema also experience other atopic conditions, such as asthma, allergic rhinitis (hay fever), or food allergies. It is the most common chronic skin disease in children. The defining feature is dry, itchy skin that can progress into red, inflamed lesions during flare-ups. A range of internal and external triggers can provoke these flares, leading to inflammation, increased blood flow, and severe itching. This causes a persistent itch-scratch cycle, which may result in skin thickening (lichenification), discoloration, dryness, and secondary infections.

The pathophysiology of AD is complex, involving skin barrier defects, immune dysregulation, IgE-mediated hypersensitivity, and environmental influences. Mutations in the filaggrin (FLG) gene are strongly linked to more severe forms of AD, as they promote water loss, elevate skin pH, and increase dehydration. Other genetic variations may further weaken the skin barrier, heightening susceptibility. An imbalance between Th2 and Th1 cytokines contributes to excessive IgE production and abnormal immune activity. On a microscopic scale, spongiosis (fluid accumulation between skin cells) facilitates the infiltration of inflammatory mediators. Various dendritic cells-including Langerhans cells, inflammatory dendritic epidermal cells, and plasmacytoid dendritic cells-play vital roles in driving disease progression.

Request for a detailed insights report on Atopic Dermatitis pipeline insights [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Atopic Dermatitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.

Key Takeaways from the Atopic Dermatitis Pipeline Report

*
DelveInsight's Atopic Dermatitis Pipeline Report highlights a vibrant and evolving landscape, with over 100 active companies developing more than 120 investigational therapies aimed at advancing Atopic Dermatitis (AD) treatment.

*
In September 2025, Incyte Corporation's topical Opzelura (ruxolitinib cream 1.5 %) was approved by the FDA for children aged 2 to 11 with mild-to-moderate AD whose disease is not adequately controlled with topical therapies.

*
In October 2025, Arcutis Biotherapeutics's topical Zoryve (roflumilast cream 0.05 %) received FDA approval for children aged 2 to 5 with mild-to-moderate AD.

*
In October 2025, Eli Lilly and Company reported promising long-term data for its biologic Ebglyss (lebrikizumab) in adolescents with moderate-to-severe AD, and has submitted label-expansion data to the FDA.

*
The FDA has extended the PDUFA review deadline to September 19, 2025, for the 0.75% ruxolitinib cream supplemental application targeting children aged 2-11 years with mild-to-moderate AD, allowing additional time to review updated chemistry, manufacturing, and control (CMC) data.

*
In December 2024, the FDA approved Nemluvio, the first IL-31 receptor A-targeting therapy, for patients aged 12 and older with moderate-to-severe AD not adequately controlled by topical corticosteroids or calcineurin inhibitors, offering relief from itch and inflammation.

*
Similarly, in September 2024, Ebglyss received FDA approval for patients aged 12 and above with moderate-to-severe AD. This once-monthly injectable biologic, which neutralizes IL-13, demonstrated strong efficacy in clinical trials involving over 1,000 participants.

*
Leading companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, and Astria Therapeutics are actively working to reshape the AD treatment landscape through innovative drug development.

*
Prominent pipeline candidates across various stages include ICP-332, APG777, Barzolvolimab, ATI-2138, STAR-0310, and several others showing promising therapeutic potential.

Atopic Dermatitis Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.

Download our free sample page report on Atopic Dermatitis pipeline insights [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Atopic Dermatitis Emerging Drugs

ICP-332 - InnoCare Pharma

ICP-332 is a potent and highly selective TYK2 inhibitor under development for treating several T-cell-mediated autoimmune disorders, including atopic dermatitis (AD), vitiligo, and inflammatory bowel disease (IBD).

TYK2, a non-receptor tyrosine kinase belonging to the JAK family, is a crucial component of the JAK-STAT signaling pathway, which regulates immune and inflammatory responses. By targeting this pathway, ICP-332 offers broad therapeutic potential across multiple inflammatory conditions. The drug is currently in Phase III clinical trials for atopic dermatitis.

APG777 - Apogee Therapeutics

APG777 is a novel, long-acting monoclonal antibody administered subcutaneously, specifically engineered to target interleukin-13 (IL-13) for the treatment of atopic dermatitis (AD).

In preclinical studies, APG777 exhibited comparable or superior efficacy to lebrikizumab in inhibiting IL-13 signaling. Results from a 12-month Phase I trial demonstrated an extended half-life of 77 days, a strong safety profile, and favorable pharmacodynamic outcomes. A single dose achieved near-complete inhibition of pSTAT6 and sustained suppression of TARC levels for up to one year. The therapy is currently being evaluated in Phase II clinical trials for atopic dermatitis.APG777 is a novel, long-acting monoclonal antibody administered subcutaneously, specifically engineered to target interleukin-13 (IL-13) for the treatment of atopic dermatitis (AD).

Atopic Dermatitis Companies

Over 100 prominent companies are actively engaged in developing therapies for Atopic Dermatitis. Among them, InnoCare Pharma is one of the companies with a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 75+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Atopic Dermatitis Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Atopic Dermatitis Pipeline Therapeutic Assessment

- Atopic Dermatitis Assessment by Product Type

- Atopic Dermatitis By Stage

- Atopic Dermatitis Assessment by Route of Administration

- Atopic Dermatitis Assessment by Molecule Type

Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Atopic Dermatitis Current Treatment Patterns

4. Atopic Dermatitis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Atopic Dermatitis Late-Stage Products (Phase-III)

7. Atopic Dermatitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Atopic Dermatitis Discontinued Products

13. Atopic Dermatitis Product Profiles

14. Atopic Dermatitis Key Companies

15. Atopic Dermatitis Key Products

16. Dormant and Discontinued Products

17. Atopic Dermatitis Unmet Needs

18. Atopic Dermatitis Future Perspectives

19. Atopic Dermatitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Atopic Dermatitis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-clinical-companies-therapy-assessment-therapies-pipeline-vanda-pharmaceuticals-technoderma-medicines-asana-biosciences-artax-biopharma-corvus-pharmaceuticals-yuhan-biover]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.